US-based Topica Pharmaceuticals secured $27m of series B funding yesterday from investors including Yasuda Enterprise Development Corp., a venture capital (VC) firm backed by Japan-based insurance company Meiji Yasuda Life. Also participating in the round were VC firm Prospect Venture Partners and VC fund Third Rock Ventures. The funding will be used to conduct clinical…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
